A Tumor-Associated and Self Antigen Peptide Presented by Dendritic Cells May Induce T Cell Anergy in Vivo, but IL-12 Can Prevent or Revert the Anergic State

Journal of Immunology

Volumn 158, Issue 8, 1997, Pages 3593-3602

  Grohmann, Ursula ^a   Bianchi, Roberta ^a   Ayroldi, Emira ^a   Belladonna, Maria Laura ^a   Surace, Daniela ^b   Fioretti, Maria Cristina ^a   Puccetti, Paolo ^a,c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANIMAL; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; DBA MOUSE; DENDRITIC CELL; IMMUNOLOGY; MOUSE; TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; INTERLEUKIN-12; MICE; MICE, INBRED DBA; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031569513     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. Van den Eynde, B., B. Lethé, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
3. Lethe, B., B. Van den Eynde, A. Van Pel, G. Corradin, and T. Boon. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:2283.
4. Uyttenhove, C., J. Maryansky, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040.
5. d and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur. J. Immunol. 24:2740.
6. Kündig, T. M., A. Althage, H. Hengartner, and R. M. Zinkernagel. 1992. Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. USA 89: 7757.
7. + T cell reactivity. Eur. J. Immunol. 24:1446.
8. - or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur. J. Immunol. 25:2797.
9. Bianchi, R., U. Grohmann, M. L. Belladonna, S. Silla, F. Fallarino, E. Ayroldi, M. C. Fioretti, and P. Puccetti. 1996. IL-12 is both required and sufficient for initiating T-cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157:1589.
10. Fallarino, F., C. Uyttenhove, T. Boon, and T. F. Gajewsky. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095.
11. Levraud, J.-P., C. Pannetier, P. Langlade-Demoyen, V. Brichard, and P. Kourilsky. 1996. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the P815 murine tumor. J. Exp. Med. 183: 439.
12. Nossal, G. J. 1994. Negative selection of lymphocytes. Cell 76:229.
13. Quill, H. 1996. Anergy as a mechanism of peripheral T cell tolerance. J. Immunol. 156:1325.
14. Burstein, H. J., and A. K. Abbas. 1993. In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J. Exp. Med. 177:457.
15. Wraith, D. C. 1995. Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Int. Arch. Allergy Immunol. 108:355.
16. Schwanz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
17. Jones, L. A., L. T. Chin, D. L. Longo, and A. M. Kruisbeek. 1990. Peripheral clonal elimination of functional T cells. Science 250:1726.
18. Hammerling, G. J., G. Schonrich, I. Ferber, and B. Arnold. 1993. Peripheral tolerance as a multi-step mechanism. Immunol. Rev. 133:93.
19. Russell, J. H. 1995. Activation-induced death of mature T cells in the regulation of immune responses. Curr. Opin. Immunol. 7:328.
20. Falb, D., T. J. Briner, G. H. Sunshine, C. R. Bourque, M. Luqman, M. L. Gefter, and T. Kamradt. 1996. Peripheral tolerance in T cell receptor-transgenic mice: evidence for T cell anergy. Eur. J. Immunol. 26:130.
21. Cohen, J. J. 1993. Apoptosis. Immunol. Today 14:126.
22. Critchfield, J. M., and M. J. Lenardo. 1995. Antigen-induced programmed T cell death as a new approach to immune therapy. Clin. Immunol. Immunopathol. 75:13.
23. Heeg, K., and H. Wagner. 1995. Induction of responsiveness in superantigen-induced anergic T cells. J. Immunol. 155:83.
24. Lombardi, G., S. Sidhu, R. Batchelor, and R. Lechler. 1994. Anergic T cells as suppressor cells in vitro. Science 264:1587.
25. g7 molecules from non-obese diabetic mice are poor peptide binders. J. Immunol. 156:450.
26. Sette, A., J. Sidney, M. Albertson, C. Miles, S. M. Colon, T. Pedrazzini, A. G. Lamont, and H. M. Grey. 1990. A novel approach to the generation of high affinity class II-binding peptides. J. Immunol. 145:1809.
27. Nicoletti, I., G. Migliorati, C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139:271.
28. Vaux, D. L., and A. Strasser. 1996. The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA 93:2239.
29. Becker, J. C., T. Brabletz, T. Kirchner, C. T. Conrad, E. B. Brocker, and R. A. Reisfeld. 1995. Negative transcriptional regulation in anergic T cells. Proc. Natl. Acad. Sci. USA 92:2375.
30. + T cells. Science 271:1276.
31. Kawai, K., and P. S. Ohashi. 1995. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature 374:68.
32. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
33. Ridgway, W. M., H. L. Weiner, and C. G. Fathman. 1994. Regulation of autoimmune response. Curr. Opin. Immunol. 6:946.
34. Gajewski, T. F., J.-C. Renhauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. 154:5637.
35. Trinchieri, G. 1994. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
36. Brunda, M. J., and M. K. Gately. 1995. Interleukin-12: potential role in cancer therapy. In Important Advances in Oncology. V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds. Lippincott Co., Philadelphia, p. 3.
37. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. Clarke, M. Nalesnik, M. K. Gately, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with interleukin-12 (IL-12): effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.
38. Noguchi, Y., E. C. Richards, Y.-T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established MethA sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
39. Müller, G., J. Saloga, T. Germann, G. Schuler, J. Knop, and A. H. Enk. 1995. IL-12 as mediator and adjuvant for the induction of contact sensitivity in vivo. J. Immunol. 155:4661.
40. Riemann, H., A. Schwarz, S. Grabbe, Y. Aragane, T. A. Luger, M. Wysocka, M. Kubin, G. Trinchieri, and T. Schwarz. 1996. Neutralization of IL-12 in vivo prevents induction of contact hypersensitivity and induces hapten-specific tolerance. J. Immunol. 156:1799.
41. + T cells from human immunodeficiency virus-infected persons. J. Exp. Med. 182:1759.
42. Becker, J. C., and E. B. Brocker. 1994. Prevention of anergy induction in cloned T cells by interleukin 12. Exp. Dermatol. 3:283.
43. Quill, H., A. Bhandoola, G. Trinchieri, J. Haluskey, and D. Peritt. 1994. Induction of interleukin 12 responsiveness is impaired in anergic T lymphocytes. J. Exp. Med. 179:1065.
44. Lamont, A. G., and L. Adorini. 1996. IL-12: a key cytokine in immune regulation. Immunol. Today 17:214.
45. Leonard, J. P., K. E. Walderburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12. J. Exp. Med. 181:381.
46. Germann, T., J. Szeliga, H. Hess, S. Stoerkel, F. J. Podlaski, M. K. Gately, E. Schmitt, and E. Rüde. 1995. Administration of IL-12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA 92:4823.
47. fyn expression. Eur. J. Immunol. 24:558.
48. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
49. Uyttenhove, C., C. Godfraind, B. Lethé, A. Amar-Costesec, J.-C. Renauld, T. F. Gajewski, M.-T. Duffour, G. Warmer, T. Boon, and B. J. Van den Eynde. 1997. The expression of mouse gene PlA in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer, in press.
50. Nelson, C. A., S. J. Petzold, and E. R. Unanue. 1993. Identification of two distinct properties of class II major histocompatibility complex-associated peptides. Proc. Natl. Acad. Sci. USA 90:1227.
51. Toes, R. E. M., R. J. J. Blom, R. Offringa, W. M. Kast, and C. J. M. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination: functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911.
52. Finkelman, F. D., A. Lees, R. Birnbaum, W. C. Gause, and S. C. Morris. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157:1406.
53. Young, J. W., and K. Inaba. 1996. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7.
54. Adorini, L., J. Magram, and S. Trembeau. 1995. The role of endogenous IL12 in the induction of Th1-cell-mediated autoimmune diseases. Res. Immunol. 146: 645.